ProCE Banner Activity

ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs

Slideset Download
Conference Coverage
At Week 24, asciminib significantly improved MMR rate compared with bosutinib (25.5% vs 13.2%, respectively) with numerically lower rates of AEs leading to discontinuation, dose adjustment, or the requirement for additional therapy.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology